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1. Introduction 
Hepatocellular carcinoma (HCC) is typically diagnosed late in the course of patients 
with chronic liver disease and cirrhosis. Hepatic reserve of the patient, as indicated by 
the Barcelona Clinic or Child-Pugh staging system, can be helpful in determining 
therapeutic options. Because of rapidly evolving new treatment options and varying 
availability of therapeutic approaches to individual patients attempts in generating 
algorithmic approaches for the treatment of patients with hepatocellular carcinoma may 
not be applicable to all situations. General treatment options can be divided into 
surgical or non-surgical approaches. Non-surgical approaches may be liver directed 
(such as transarterial chemoembolozation, percutaneous ethanol injection, radiofrequency 
ablation) or sysytemic therapy. Systemic palliative therapy of HCC has not been used 
routinely for a number of reasons; First, due to high rate of expression of drug 
resistance genes, including p-glycoprotein, glutathione-S-transferase, heat shock 
proteins, and mutations in p53, HCC has been considered a relatively chemotherapy-
refractory tumor. Second, systemic chemotherapy has been difficult to be tolerated by 
patients with significant underlying hepatic dysfunction and may have less efficacy in 
patients with significant cirrhosis. Third, clinical investigations of chemotherapy in 
advanced HCC have been undertaken in diverse patient populations (Asian versus 
North American/European) making the interpretation of the results difficult for the 
overall population. Recently there has been a resurgence of interest and enthusiasm for 
systemic therapy of HCC with the emergence of data showing benefit from several 
targeted therapies. 
This chapter will focus on the non-surgical systemic treatment of HCC which includes 
chemotherapy, immunotherapy, molecularly targeted therapy, hormonal therapy, 
Immunomodulatory/antiangiogenic therapy and ongoing clinical trials of new targeted 
agents. 
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2. Chemotherapy/immunotherapy  
2.1 Single agent regimens 
2.1.1 Antracyclines 
Although there is no approved treatment for HCC in the United States, the European Union, 
or elsewhere in the world, doxorubicin has been commonly used as a first-line 
chemotherapy treatment for this disease. First approved by the US Food and Drug 
Administration in 1974 for breast cancer, doxorubicin has been the subject of multiple 
clinical trials in HCC. Early encouraging response rates as high as 79% of doxorubicin single 
agent (Olweny et al.,1975) has not been supported by later studies. Most studies have 
reported an objective response rate around 20 percent with doxorubicin doses of 75 mg/m2. 
Despite the modest objective response rate one clinical trial involving 106 patients has 
shown that doxorubicin had a small survival advantage compared to  best supportive care 
alone (median survival 10.6 versus 7.5 weeks)(Lai et al.,1988)  While the clinical trials that 
occurred from 1977 to 1990 performed in HCC with doxorubicin as a single agent at doses 
ranging from 40 to 75 mg/m2 demonstrated a survival range from 3.0 to 4.1 months, (Ihde 
et al., 1977; Johnson et al.,1978; Falkson et al., 1984a; Falkson et al., 1984b; Colombo et 
al.,1985; Melia et al.,1987;  Kalayci C et al., 1990) a more recent trial comparing single agent 
doxorubicin to nolatrexed showed a median survival of 32 versus 22 weeks in favor of 
doxorubicin (Gish et al.,2007). The higher than expected survival in both treatment groups 
might be due to advances in the management of patients with HCC including better 
supportive therapies, such as growth factors and greater expertise in the treatment of 
patients with cirrhosis. A limited number of phase III studies note higher response rates but 
no survival benefit with doxorubicin monotherapy compared to non-oxaliplatin 5-FU-based 
regimens and single agent etoposide (Choi et al.,1984; Falkson et al., 1978;  Melia et al.,1983).  
Both epirubicin and mitoxantrone have an approximately similar level of antitumor efficacy as 
doxorubicin (response rates 10 to 25 percent) (Pohl et al.,2001; Dunk et al.,1985). In contrast, the 
single agent activity of pegylated liposomal doxorubicin (PLD) is limited (Lind et al., 2007). 
2.1.2 Fluoropyrimidines 
Although there is extensive hepatic metabolism, 5-Fluorouracil (5-FU) has been utilized in 
the treatment of HCC with acceptable low toxicity and efficacy. Adequate doses have been 
able to be administered in the setting of hepatic dysfunction or jaundice. Response rates 
with 5-FU monotherapy have been low. However, when given in combination with 
leucovorin, response rates as high as 28 percent have been reported (Porta et al., 1995). 
While single agent treatment with the oral  fluoropyrimidine capecitabine (Patt et al., 2004) 
has shown an encouraging  25%  response rate in one small study, a lower objective 
response rate (three partial responses among 50 treated patients) was noted in a subsequent 
larger phase II study evaluating the same dose of capecitabine in combination with 
oxaliplatin (Bogie et al., 2007). 
2.2 Interferon alfa immunotherapy 
Although interferon alfa has shown activity in preclinical models against HCC, several 
clinical trials have shown inconclusive results. An early Chinese randomized trial of 75 
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patients suggested superior response rates and better tolerability of interferon alfa 
compared to single agent doxorubicin (Lai et al., 1989). In another randomized trial, 75 
patients with inoperable HCC were randomly assigned to receive interferon alfa 50 
mU/m2 intramuscularly three times weekly or best supportive care. Reported median 
survival was significantly improved in the interferon group (14.5 versus 7.5 weeks) with an 
objective response rate of 31 percent. Treatment was well tolerated with fatigue being the 
most common side effect requiring a dose reduction in only 34 percent of patients (Lai et al., 
1993). On the contrary in a second trial utilizing a much lower dose of interferon alfa 3 mU 
three times weekly for one year versus symptomatic treatment only 6.6 percent of patients 
achieved a partial response with no survival benefit (Llovet et al., 2000). 
Other chemotherapy and immunotherapy single agents with reported modest activity 
(mostly partial response and/or disease stabilization in HCC include irinotecan, 
gemcitabine and thalidomide (O`Reilly et al., 2002; Yang et al. et al., 2000; Lin et al., 2005). 
2.3 Combination chemotherapy and immunotherapy regimens 
2.3.1 Folfox 
In an Asian trial of 371 patients with advanced or metastatic HCC modified FOLFOX-4 was 
directly compared to single agent doxorubicin (50 mg/m2 every three weeks) the median 
survival in the FOLFOX arm, was  6.5 versus 4.9 months, p = .00425. FOLFOX was associated 
with   better median PFS, objective response rate, and disease control rate, 53 versus 33 
percent. Although the FOLFOX group had higher sensory neuropathy, most cases were mild, 
and there were no significant differences in the rate of grade 3 or 4 toxicities(Qin et al., 2010).  
2.3.2 Xelox 
Bogie et al. evaluated capecitabine (1000 mg/m2 twice daily for 14 of every 21 days) in 
combination with oxaliplatin (130 mg/m2 every three weeks), there were only three 
partial responses among 50 treated patients (objective response rate 6 percent) Stable 
disease in 29 patients led to a disease control rate of 72 percent. Median overall and 
progression-free survival was 9.3 and 4.1 months, respectively (Bogie et al. 2007). 
2.3.3 Gemox 
In a phase II study involving 32 cirrhotic patients with previously untreated advanced HCC, 
gemcitabine (1000 mg/m2 by fixed dose rate infusion) on day 1 was followed by oxaliplatin 
(100 mg/m2) on day 2, with both drugs repeated every two weeks. The objective response 
rate was 18 percent, and an additional 58 percent had disease stabilization. Median survival 
was 11.5 months. Treatment seemed to be more effective in patients with nonalcoholic 
rather than alcoholic cirrhosis (Louafi et al., 2007). 
2.4 Gemcitabine plus pegylated liposomal doxorubicin 
In a phase II trial, 41 patients were treated with gemcitabine (1000 mg/m2 days 1 and 8) plus 
pegylated liposomal doxorubicin (30 mg/m2 on day 1) every 28 days. There were three 
complete and seven partial responses (overall response rate 24 percent), the median TTP 
was 5.8 months, and median overall survival was 22.5 months. Treatment was well 
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tolerated, with grade 3 to 4 toxicity limited to neutropenia (17 percent) and 
thrombocytopenia (2 percent) (Lombardi et al. 2011). 
2.5 Gemcitabine and cisplatin 
Parikh et al. evaluated the combination of gemcitabine (1250 mg/m2 on days 1 and 8) and 
cisplatin (70 mg/m2 on day 1 of every 21-day cycle) was associated with an overall response 
rate of 20 percent (Parikh et al., 2005). Grade 3 to 4 toxicities included anemia (37 percent), 
neutropenia (13 percent), thrombocytopenia (7 percent), transaminitis and mucositis (3 percent 
each). A second trial using a slightly different dosing regimen (cisplatin 25 mg/m2 on days 1 
and 8, gemcitabine 1000 mg/m2 on days 1 and 8) reported a more favorable toxicity profile but 
a lower response rate (one partial response among 15 patients (Chia et al., 2008).  
Other combination regimens include cisplatin plus doxorubicin with response rates 18 to 49 
percent (Lee et al., 2004; Czauderna et al., 2002), cisplatin, mitoxantrone, and continuous 
infusion 5-FU with objective response rates 24 to 27 percent in two different studies (Yang et 
al., 2004; Ikeda et al., 2005), cisplatin, epirubicin and infusional 5-FU with a response rate 15 
percent (Boucher et al., 2002;) cisplatin, doxorubicin plus capecitabine with a response rate 
of 24 percent (Park et al., 2006).  
2.6 Combination of chemotherapy with interferon-alfa 
2.6.1 The PIAF regimen 
The immunomodulatory cytokine interferon alfa has been utilized in combination with 
different chemotherapy drugs in the treatment of HCC. One of the most aggressive 
combinations of  this drug involves cisplatin, interferon alfa and infusional 5-FU, the so 
called PIAF regimen. Leung et al. evaluated this combination in 50 advanced stage HCC 
patients and found  an objective response rate of 26 percent. Overall median survival of the 
entire population was nine months and eight of the resected patients remained in complete 
remission from eight to 26 months. Toxicity was mainly myelosupression and mucositis 
with  no treatment related deaths (Leung et al., 1999). In another trial 188 unselected patients 
with chemotherapy-naive unresectable HCC were randomly assigned to doxorubicin 
monotherapy (60 mg/m2 every three weeks) versus PIAF (cisplatin 20 mg/m2 on days 1 
through 4, interferon alfa 5 MU/m2 subcutaneously on days 1 through 4, doxorubicin 40 
mg/m2 on day 1, and 5-FU 400 mg/m2 on days 1 through 4) (Yeo et al., 2005). Objective 
response rates and median survival favored the PIAF regimen but the difference did not 
reach  statistical significance. Toxicity was more in the PIAF arm, with more pronounced 
myelosupression and hypokalemia (Yeo et al.,2005). 
Although  the role of PIAF regimen in the treatment of HCC remains unclear, it may be 
considered for patients with a good performance status and liver function. 
2.6.2 5-FU plus interferon alfa 
Patt et al. evaluated 43 patients with advanced HCC on a regimen of infusional 5-FU (200 
mg/m2 daily for 21 of  28 days) plus interferon alfa (4 mU/m2 three times weekly and 
found an objective response rate of 33 percent(Patt et al.,2003 (Patt et al., 2003). Two of four 
patients with HCC who were subsequently resected had a complete histologic response. 
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Despite the presence of cirrhosis in 71 percent of the patients with HCC, toxicity was 
moderate, with grade 3 or 4 stomatitis, fatigue, and hematologic toxicity in 33, 5, and 9 
percent of patients, respectively. A similar level of benefit (objective response rates between 
33 and 50 percent, one-third to one-half complete) has been seen with combinations of 
systemic interferon alfa with intrahepatic arterial 5-FU in patients with advanced HCC and 
major portal vein thrombus (a contraindication to transhepatic arterial chemoembolization) 
(Sakon et al., 2002; Ota et al., 2005; Nagano et al. 2007). A weekly bolus regimen of 5-FU 750 
mg/m2 plus interferon alfa 9 MU three times weekly however, was much more toxic and 
ineffective in a small series of 10 patients with no sustainable responses (Stuart et al., 1996). 
3. Molecularly targeted therapy 
Existing evidence points to the possible role of epidermal growth factor receptor 
(EGFR)/EGF (HER1) signaling pathway in the carcinogenesis of HCC (Huether et al.,2005; 
Hung et al., 1993; Yamaguchi et al., 1995; Myaki et al., 2000; Schiffer et al.., 2005; Hopfner et 
al., 2004; Wu et al., 2003; Ito et al., 2001; Thomas et al., 2005). These data have led to the 
clinical trials evaluating the role of biologics such as erlotinib and cetuximab in HCC 
patients. HCCs are highly vascular tumors with high levels of expression of vascular 
endothelial growth factor (VEGF), thus suggesting a possible therapeutic role for agents 
targeting VEGF and/or the VEGF receptor (VEGFR). Similarly the Raf/MAP kinase 
pathway has been implicated in HCC tumorigenesis (Huynh et al.,2003) with a potential 
therapeutic role for drugs that inhibit Raf kinase pathway. There is a constant research to 
find less toxic more active targeted treatments in this disease. 
3.1 Sorafenib 
Efficacy of sorafenib, an oral small molecule tyrosine kinase inhibitor, was first noted on a 
phase I trial (Liu I et al., 2006; Strumberg D. et al., 2005). Further studies did not suggest a 
high level of objective tumor shrinkage but provided stable disease (Abou-Alfa GK et al., 
2006). Eventually SHARP trial confirmed a survival benefit compared to best supportive 
care alone. SHARP trial randomly assigned 602 patients with inoperable HCC and Child-
Pugh A cirrhosis to sorafenib (400 mg twice daily) versus placebo (Llovet et al., 2008). 
Overall survival, the primary endpoint, was significantly longer in the sorafenib-treated 
patients (10.7 versus 7.9 months), as was time to radiologic progression 
(5.5versus2.8months). Treatment was well tolerated with manageable side effects. These 
results established sorafenib monotherapy as the new reference standard systemic treatment 
for advanced HCC. In another trial 226 Asian patients with Child-Pugh A cirrhosis and no 
prior systemic therapy for HCC received sorafenib 400 mg twice daily versus placebo 
(Cheng et al., 2009). Patients receiving sorafenib had significantly better median overall 
survival (6.5 versus 4.2 months) and TTP (2.8 versus 1.4 months). The treated group in the 
Asian trial had a shorter survival duration than the control group in the SHARP trial (6.5 
versus 7.9 months), despite the fact that both trials used the same entry criteria. Patients 
accrued to the Asian study were more ill at the start of therapy than those in the SHARP trial, 
with a generally worse performance status and more advanced stage of disease (Raoul et al., 
2008). Preliminary data suggest that patients with hepatitis C virus (HCV) infection as the 
etiology of their cirrhosis may have a better response to sorafenib as compared to those with 
other etiologies of the HCC (Huitzel-Melendez et al., 2007; Bolondi et al., 2008). However, the 
available data are scant, and further study is needed to establish the influence of underlying 
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liver disease on sorafenib treatment responsiveness. With the advances in our understanding 
of the pathophysiology of this disease and the development of new biomarkers, we may be 
able to better identify patients who might benefit most from sorafenib treatment. 
3.2 Sorafenib plus doxorubicin 
The benefit of adding sorafenib to doxorubicin was studied in a phase II trial in which all 
patients received doxorubicin (60 mg/m2 every 21 days), and they were randomly assigned 
to sorafenib 400 twice daily for a maximum of six cycles or placebo (Abou-Alfa et al., 2010). 
Combination therapy was associated with a similarly low objective response rate (4 versus 2 
percent with doxorubicin alone), but a significantly longer time to tumor progression (6.4 
versus 2.8 months) and median overall survival duration (13.7 versus 6.5 months). The side 
effect profile was not significantly worse with combined therapy. 
The degree to which this improvement represents synergism between sorafenib and 
doxorubicin remains to be defined. Before this approach can be considered standard, this 
combination must be compared to sorafenib alone in a large-scale phase III trial, which is 
ongoing. 
3.3 Sunitinib 
Sunitinib is another orally active TKI that targets a variety of TKs in addition to VEGFR, 
including platelet-derived growth factor receptors (PDGFRs), KIT, RET, and FLT3. Antitumor 
activity is suggested by the following early observations:A phase II study included 37 patients 
with unresectable HCC who were treated with sunitinib (50 mg daily for four of every six 
weeks) and assessed by monthly CT scans (Faivre et al.,2009). There was one confirmed partial 
response, and 35 percent had stable disease for over three months. 
3.4 Small molecule TK inhibitors 
Small molecule TKI, erlotinib  has shown some activity in phase II studies of advanced HCC 
patients with tumors expressing EGFR/HER1. Philip et al. treated 38 patients with advanced 
HCC, one half of whom had prior chemotherapy using 150 mg of erlotinib orally daily on 28- 
day cycles. Twelve patients out of 38 (32 percent) were progression free at six months while 
three had a radiographic response that lasted for two, 10 and 11 months respectively. (Philip et 
al., 2005). The median survival of the entire cohort was 13 months. A second trial included 40 
patients with previously untreated unresectable HCC who received erlotinib 150 mg daily as 
monotherapy (Thomas et al., 2007). There were no objective responses, but 17 achieved stable 
disease with 16 weeks of continuous therapy. The median overall survival was 11 months. 
Additional studies with other receptor TKIs, both as monotherapy and in combination with 
cytotoxic chemotherapy are ongoing. 
3.5 Bevacizumab 
Bevacizumab, a monoclonal antibody against the VEGF, has been shown to be active in 
HCC. In one study involving 46 patients with locally advanced HCC single agent 
bevacizumab was given at 5 mg/kg or 10 mg/kg every two weeks.(Siegel et al.,2008) An 
objective response was documented in six (13 percent, one complete), and the median 
progression-free survival was 6.9 months. The most common grade 3 or 4 toxicities were 
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hypertension (15 percent), thrombosis (6 percent) and major bleeding (11 percent). A similar 
level of efficacy was seen in a second trial, reported in abstract form only (Malka et al., 
2007). Using bevacizumab 5 to 10 mg/kg every 14 days, there were three partial responses 
and 13 disease stabilizations among 30 patients, and six had to discontinue therapy because 
of variceal bleeding. 
3.6 Erlotinib plus bevacizumab 
In a study of bevacizumab (10 mg/kg every two weeks) plus erlotinib (150 mg orally daily, 
continuously), was associated with a response rate of 25 percent and a stable disease rate of 
37 percent. The median progression-free and overall survival durations were 9 and 15.6 
months, respectively (Thomas et al.,2009). These results appear favorable compared with 
those reported in phase II and III trials of sorafenib as a single agent (median survival 6.5 to 
14 months). Randomized trials are  needed to confirm the superiority of erlotinib and 
bevacizumab over other systemic regimens. 
3.7 Bevacizumab plus gemcitabine plus oxaliplatin 
In a small phase II trial 30 patients received gemcitabine (1000 mg/m2) followed by 
oxaliplatin (85 mg/m2) on days 2 and 16, plus bevacizumab (10 mg/m2 on day 1 of the first 
cycle and thereafter, on days 1 and 15 of each cycle) (Zhu et al., 2006). The objective response 
rate was 20 percent, the six-month progression-free survival rate was 48 percent, and 
median overall survival was 9.6 months. Whether any combination regimens are better than 
bevacizumab alone will require a randomized trial.  
3.8 Cetuximab 
Early results suggest activity for cetuximab in combination with GEMOX (Louafi et al., 
2007). In a preliminary report of 44 patients who received gemcitabine 1000 mg/m2 on day 1 
and oxaliplatin 100 mg/m2 on day 2 every 14 days, in combination with cetuximab (400 
mg/m2 initially, then 250 mg/m2 weekly), there were eight partial responses, and the total 
disease control rate (partial response plus stable disease) was 65 percent. Treatment was 
well tolerated with only one grade 4 toxicity (thrombocytopenia) and no grade 5 toxicities. 
Grade 2 and 3 neurotoxicity occurred in 16 and 5 percent of patients, respectively. 
4. Hormone therapy 
4.1 Tamoxifen 
HCC known to express hormonal receptors and the striking gender disparity observed in 
the incidence of hepatocellular carcinoma has suggested an important role of sex hormones 
in HCC pathogenesis. Though the studies began as early as in 1980s, the precise role of sex 
hormones and the significance of their receptors in HCC still remain poorly understood and 
perhaps contribute to current controversies about the potential use of hormonal therapy in 
HCC(Kalra M et al., 2008). Several prospective randomized trials and a systematic review of 
tamoxifen in patients with advanced HCC have failed to show a survival benefit or 
improved functional status (Castells et al., 1995; Chow et al., 2002; Nowak et al., 2004; 
Barbare et al., 2005). One possible reason for the lack of efficacy may be the presence of 
variant ERs in some of these tumors (Villa et al., 1996; Villa et al., 2001). Tamoxifen may also 
function as a potential inhibitor of p-glycoprotein, the MDR (multidrug resistance) gene 
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product, and this has led to trials of tamoxifen combined with various chemotherapeutic 
agents. Unfortunately, these studies have also failed to demonstrate any benefit for the 
addition of tamoxifen (Cheng et al.., 1996; Raderer et al., 1996). 
4.2 Megestrol 
Unlike tamoxifen there has been some modest benefit with the use of megestrol in some 
studies involving patients with HCC. In a study of 24 patients with advanced HCC who were 
randomly assigned to megestrol (160 mg daily) or supportive care only, median survival was 
significantly better with megestrol (18 versus 7 months) despite no objective responses(Farinati 
et al., 2001). In  another study, one of 37 patients receiving megestrol (160 mg daily) for at least 
60 days had a partial response, while two others had a significant decline in serum alpha-
fetoprotein (AFP) levels (Chao et al., 1997).  
4.3 Octreotide and lanreotide 
In a review of four randomized controlled trials (three of which were high quality trials) 
published in 1998 or later with a total of 373 patients only one (126 patients) suggested that 
octreotide could improve survival and quality of life of HCC patients, whereas the other 
two(189 patients) suggested octreotide did not have survival benefit in HCC; moreover, none 
of the three trials indicated that octreotide has significant beneficial effect on tumor regression 
or decrease of tumor mass. Nonetheless, serious adverse effects were not reported in these 
included trials. In order to detect a realistic treatment advantage, further larger well-designed 
multicenter randomized trials will have to be conducted(Jia et al., 2010).  
Lanreotide is a long acting somatostatin analog that is available in a depot formulation that 
has comparable efficacy to octreotide when injected intramuscularly two to three times per 
month. Although limited antitumor activity has been suggested in nonrandomized studies a 
randomized trial of lanreotide versus placebo in 272 patients with advanced HCC failed to 
show any advantage for drug treatment in terms of progression-free or overall survival, and 
treatment was associated with worse quality of life (Barbare et al., 2009). 
5. Immunomodulatory/antiangiogenic therapy 
5.1 Lenalidomide 
Last but not he least, Lenalidomide, an immunomodulatory analog of thalidomide, an anti-
angiogenic agent with inhibitiory effects on basic fibroblast growth factor (FGF) and vascular 
endothelial growth factor (VEGF) has shown promising and in some patients dramatic 
activity. FGF is an important growth factor in HCC. In a phase II study to determine the 
activity of lenalidomide in Second-line HCC therapy, patients with advanced HCC who 
progressed or were intolerant to sorafenib  were  treated with lenalidomide 25 mg orally days 
1-21 of a 28 day cycle until disease progression or unacceptable toxicity. A preplanned interim 
analysis was undertaken when study enrollment reached 13 out of the total planned 40 
patients. Of the first 13 patients, the median age was 66 years (44-86 years). Eight patients were 
Child-Pugh A, 3 patients were B, and 2 patients were C. Nine patients had extrahepatic 
disease. Five of 13 patients (38%) had a > 50% reduction in AFP including one patient with a 
reduction in AFP from 56,900 to 5 ng/mL. Two patients had radiographic partial responses 
including one patient with complete resolution of all areas of enhancement. Treatment was 
well tolerated with grade 3 neutropenia seen in 2 patients (Safran et al., 2010) 
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6. Active clinical trials in HCC 
Clinical trials for patients with Advanced Hepatocellular Carcinoma (HCC) are listed below. 
The list of clinical trials includes treatment trials currently recruiting in the United States. 
Further information regarding each clinical trial can be reached at www.canliv.org/Doctors--
amp;-Researchers/Active-Clinical-Trials  
 Sorafenib and TRC105 in Hepatocellular Cancer 
 A Study of LY2157299 in Patients With Hepatocellular Carcinoma 
 Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma 
 A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care 
(BSC) Versus Placebo and BSC as 2nd-Line Treatment in Patients With Hepatocellular 
Carcinoma After 1st-Line Therapy With Sorafenib 
 A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced 
or Inoperable Hepatocellular Cancer 
 Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer 
 Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) 
and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. 
 Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular 
Carcinoma (HCC) 
 A Study of IMC-A12 in Combination With Sorafenib in Patients With Advanced Cancer 
of the Liver ABT-888 and Temozolomide for Liver Cancer  
 A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in 
Patients With Advanced HCC Bevacizumab and Erlotinib or Sorafenib as First-Line 
Therapy in Treating Patients With Advanced Liver Cancer 
7. Conclusions 
In this chapter we tried to summarize systemic therapy options for patients with advanced 
unresectable disease who are not candidates for locoregional therapy. This is a constantly  
evolving field. In general, efficacy with conventional cytotoxic chemotherapy has been 
modest at best, and the duration of benefit is limited. Although few randomized trials have 
been conducted, no single regimen seems to be superior and no drug or regimen has been 
unequivocally shown to improve survival. Newer data on the efficacy of molecularly 
targeted agents has been promising offering the potential for prolonged survival. 
Participation in ongoing clinical trials testing new therapeutic strategies is the best option 
for patients with advanced unresectable disease. For patients who are not eligible for a 
clinical trial or for whom protocol therapy is not available initial therapy  with sorafenib 400 
mg twice daily is the first line recommendation. To improve  tolerability starting at 200 mg 
twice a day and increase the daily dose in 200 mg increments approximately every five days 
until the target dose is reached is a feasible option.  
The efficacy of cytotoxic chemotherapy is at best modest in patients with HCC, and in 
general, the duration of benefit is limited. No single regimen has emerged as superior to any 
other, although few randomized trials have been conducted. Despite objective responses 
that are occasionally complete, median survival in all of these studies has been short (4.4 to 
11.6 months), with the exception of those in which resection/transplantation is attempted 
after chemotherapy. There are insufficient data to routinely recommend any standard 
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regimen. Systemic chemotherapy may still be considered for patients whose tumors 
progress while on sorafenib and whose performance status and baseline liver function are 
sufficient to tolerate it. The side effect profile of any chemotherapy regimen should be 
considered carefully in patients with advanced liver disease and a short life expectancy. 
Cytotoxic therapy should be reserved for medically appropriate patients with adequate 
hepatic function and preferably administered within the context of a clinical trial. 
Reactivation of viral hepatitis may occur in patients with HCC who are undergoing 
intensive systemic chemotherapy, so it is important to monitor and maintain antiviral 
medications during treatment. 
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